myelin loss

With Korro Bio merger in works, Frequency stops program for MS

With a planned merger in the works, Frequency Therapeutics is no longer advancing its remyelination therapies for multiple sclerosis (MS), and instead is exploring “strategic alternatives for the program,” the company has announced. The regenerative medicine company, which had aimed to develop a new approach to treating MS…

Top 10 Multiple Sclerosis Stories of 2020

Multiple Sclerosis News Today brought you daily coverage of the latest scientific findings, treatment developments, and clinical trials related to multiple sclerosis (MS) throughout 2020, a year marked by theĀ COVID-19 pandemic. We look forward to reporting more news to patients, family members, and caregivers dealing with MS during…